Table 3.
Vorinostat in combineted clinical trials.
| Drug | Conditions | Status | NCT number | Phases |
|---|---|---|---|---|
| Isotretinoi + vorinostat | Brain, neuroblastoma, CNS, hematologic tumors | Completed | NCT00217412 | Phase 1 |
| Idarubicin + vorinostat | Leukemia, myelodysplastic syndromes | Completed | NCT00331513 | Phase 1 |
| Vorinostat + gemcitabine + platinum | NSCL cancer | Completed | NCT00423449 | Phase 1 |
| Vorinostat + pemetrexed + cisplatin | Advanced cancer | Completed | NCT00106626 | Phase 1 |
| MK0683 + vorinostat | Breast cancer, colorectal cancer, NSCL | Terminated | NCT00126451 | Phase 2 |
| Vorinostat + docetaxel | NSCL, prostate, bladder, urothelial cancers | Terminated | NCT00565227 | Phase 1 |
| Vorinostat + tamoxifen | Breast cancer | Terminated | NCT01194427 | Phase 2 |
| MK0683 + vorinostat | B‐cell lymphoma | Completed | NCT00097929 | Phase 2 |
| Carboplatin + paclitaxel + vorinostat | Unspecified adult solid tumor, protocol specific | Completed | NCT00287937 | Phase 1 |
| Vorinostat, vinorelbine | Malignant solid tumor | Terminated | NCT00801151 | Phase 1 |
| Azacitidine + vorinostat | Leukemia, myelodysplastic syndromes | Suspended | NCT00392353 | Phase 1, 2 |
| Gemtuzumab ozogamicin + vorinostat | Hematologic cancer | Terminated | NCT00673153 | Phase 2 |
| MK0683, vorinostat | Cutaneous T‐cell lymphoma, mycosis fungoides | Completed | NCT00091559 | Phase 2 |
| Vorinostat + decitabine | Leukemia, acute myelodysplastic syndromes | Completed | NCT00479232 | Phase 1 |
| Fluorouracil, leucovorin calcium, oxaliplatin, vorinostat | Colorectal cancer | Completed | NCT00138177 | Phase 1 |
| Carboplatin + paclitaxel + vorinostat | Lung cancer | Completed | NCT00481078 | Phase 2 |
| Vorinostat + paclitaxel + carboplatin | Stage IIIB or IV non‐small cell lung cancer | Terminated | NCT00473889 | Phase 2, 3 |
| Chemoradiation + vorinostat | Pancreatic cancer | Terminated | NCT00831493 | Phase 1, 2 |
| Vorinostat – bexarotene | Lymphoma | Terminated with with result | NCT00127101 | Phase 1 |
| Vorinostat + tamoxifen | Breast cancer | Completed with result | NCT00365599 | Phase 2 |
| Gemcitabine + vorinostat | Unspecified adult solid tumor, protocol specific | Completed | NCT00243100 | Phase 1 |
| Vorinostat + alvocidib | Unspecified adult solid tumor, protocol specific | Completed | NCT01645514 | Phase 1 |
| Vorinostat + alvocidib | Leukemia, myelodysplastic syndromes | Completed | NCT00278330 | Phase 1 |
| Topotecan + vorinostat | Small cell lung cancer | Terminated | NCT00697476 | Phase 1, 2 |
| Vorinostat + alvocidib | Unspecified adult solid tumor, protocol specific | Completed | NCT00324480 | Phase 1 |
| Fluorouracil + leucovorin calcium + vorinostat | Hematologic and solid cancer | Completed | NCT00942266 | Phase 2 |
| MK0683, vorinostat | Neoplasms | Terminated | NCT00424775 | Phase 1 |
| MK0683, vorinostat | Cancer, advanced | Completed | NCT00750178 | Phase 1 |
| Vorinostat + bortezomib + dexamethasone | Relapsed or refractory multiple myeloma | Completed | NCT00773838 | Phase 2 |
| Vorinostat + bortezomib | Lymphoma, sarcoma, Wilms tumor, neuroblastoma | Completed | NCT01132911 | Phase 1 |
| Vorinostat + bortezomib | Unspecified adult solid tumor, protocol specific | Completed | NCT00227513 | Phase 1 |
| Vorinostat + bortezomib | Multiple myeloma | Completed | NCT00111813 | Phase 1 |
| Bortezomib + dexamethasone + vorinostat | Multiple myeloma and plasma cell neoplasm | Completed | NCT00310024 | Phase 1 |
| Vorinostat + bortezomib | Multiple myeloma | Completed | NCT00858234 | Phase 1 |
| Vorinostat + bortezomib | Leukemia, myelodysplastic syndromes | Terminated | NCT00818649 | Phase 2 |
| Vorinostat + bortezomib | Lymphoma | Terminated | NCT00810576 | Phase 2 |
| Dasatinib + vorinostat | Leukemia | Completed | NCT00816283 | Phase 1 |